-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

Benzinga·05/05/2026 18:10:34
Listen to the news
Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.